May 29, 2025, 20:14

Department of Defense Breast Cancer Research Program

The Breast Cancer Research Program (BCRP) under the Congressionally Directed Medical Research Programs (CDMRP) supports innovative, high-impact breast cancer research with clinical relevance for Service Members, Veterans, and the general public. The FY25 funding will focus on tackling key challenges in breast cancer, such as dormancy, recurrence, metastasis, overdiagnosis, and treatment innovation.

Eligibility Criteria:

Varies by award mechanism.
Generally open to independent investigators at all academic levels.
Era of Hope Scholar Award is limited to early-career investigators within 6 years of their last training.
All applicants must meet specific criteria outlined in each funding announcement.
Most awards require inclusion of two or more consumer advocates on the research team.

Funding Details:

Breakthrough Award (Levels 1–3):
- Funding: $540K–$5M (direct costs)
- Duration: 3–4 years
- For high-risk/high-reward to advanced translational studies
- Level 1: No preliminary data required
- Level 3: May support small-scale clinical trials
Era of Hope Scholar Award:
- Funding: Up to $3.5M (direct costs)
- Duration: 4 years
- For exceptionally talented early-career investigators
Clinical Research Extension Award:
- Funding: Up to $6M (direct costs)
- Duration: 4 years
- To extend and enhance data from existing breast cancer clinical research

Deadline:

Pre-application required through https://eBRAP.org
Deadlines to be announced in full Funding Opportunity Announcements (FOAs) via Grants.gov
Subscribe for updates at https://eBRAP.org

Where to go for further information:

Visit CDMRP website
Search Grants.gov using CFDA Number 12.420
Contact: CDMRP Public Affairs
- Phone: +1 301-619-9783
- Email: [email protected]

Breakthrough Award breast cancer dormancy Breast Cancer Research Program cancer cancer recurrence CDMRP Clinical Research Extension Award Department of Defense DoD cancer grants eBRAP Era of Hope Scholar FY25 BCRP metastatic breast cancer OncoDaily Oncology Translational Oncology U.S. Army Medical Research

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening

Inside ASCO25 Exhibition - Who did it the best?

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived